129 related articles for article (PubMed ID: 15356408)
1. Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women's Health in the Lund Area study.
Shakir YA; Samsioe G; Nerbrand C; Lidfeldt J;
Menopause; 2004; 11(5):549-55. PubMed ID: 15356408
[TBL] [Abstract][Full Text] [Related]
2. Effects of norethisterone acetate addition to estradiol in long term HRT.
Li C; Samsioe G; Wilaman K; Lidfelt J; Nerbrand C; Agardh CD; Schersten B
Maturitas; 2000 Aug; 36(2):139-52. PubMed ID: 11006501
[TBL] [Abstract][Full Text] [Related]
3. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
Kimmerle R; Heinemann L; Heise T; Bender R; Weyer C; Hirschberger S; Berger M
Menopause; 1999; 6(1):36-42. PubMed ID: 10100178
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
[TBL] [Abstract][Full Text] [Related]
5. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
[TBL] [Abstract][Full Text] [Related]
6. Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate.
Samsioe G; Li C; Borgfeldt C; Wilawan K; Aberg A; Larsen S
Menopause; 2002; 9(5):335-42. PubMed ID: 12218722
[TBL] [Abstract][Full Text] [Related]
7. Do sex hormones influence features of the metabolic syndrome in middle-aged women? A population-based study of Swedish women: the Women's Health in the Lund Area (WHILA) Study.
Shakir YA; Samsioe G; Nyberg P; Lidfeldt J; Nerbrand C; Agardh CD
Fertil Steril; 2007 Jul; 88(1):163-71. PubMed ID: 17383645
[TBL] [Abstract][Full Text] [Related]
8. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
Johannisson E; Holinka CF; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
[TBL] [Abstract][Full Text] [Related]
9. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
10. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate.
Campagnoli C; Colombo P; De Aloysio D; Gambacciani M; Grazioli I; Nappi C; Serra GB; Genazzani AR
Maturitas; 2002 Apr; 41(4):299-311. PubMed ID: 12034517
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
[TBL] [Abstract][Full Text] [Related]
12. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
13. Low-dose hormone therapy and carbohydrate metabolism.
Li C; Samsioe G; Borgfeldt C; Bendahl PO; Wilawan K; Aberg A
Fertil Steril; 2003 Mar; 79(3):550-5. PubMed ID: 12620438
[TBL] [Abstract][Full Text] [Related]
14. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate.
Gambacciani M; Spielmann D; Genazzani AR
Gynecol Endocrinol; 2005 Aug; 21(2):65-73. PubMed ID: 16294457
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy dependent changes in breast cancer-related gene expression in breast tissue of healthy postmenopausal women.
Sieuwerts AM; De Napoli G; van Galen A; Kloosterboer HJ; de Weerd V; Zhang H; Martens JW; Foekens JA; De Geyter C
Mol Oncol; 2011 Dec; 5(6):504-16. PubMed ID: 21956102
[TBL] [Abstract][Full Text] [Related]
16. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels.
Eviö S; Tiitinen A; Turpeinen U; Ylikorkala O
Fertil Steril; 2000 Dec; 74(6):1080-3. PubMed ID: 11119731
[TBL] [Abstract][Full Text] [Related]
17. Does the hormonal situation modify lipid effects by lifestyle factors in middle-aged women? Results from a population-based study of Swedish women: the women's health in the Lund area study.
Shakir YA; Samsioe G; Nyberg P; Lidfeldt J; Nerbrand C
Metabolism; 2006 Aug; 55(8):1060-6. PubMed ID: 16839842
[TBL] [Abstract][Full Text] [Related]
18. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
19. Effects of standard and low dose 17beta-estradiol plus norethisterone acetate on body composition and leptin in postmenopausal women at risk of body mass index and waist girth related cardiovascular and metabolic disease.
Odabasi AR; Yuksel H; Karul A; Kozaci D; Sezer SD; Onur E
Saudi Med J; 2007 Jun; 28(6):855-61. PubMed ID: 17530099
[TBL] [Abstract][Full Text] [Related]
20. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
